You are hereJune 27, 2017
What’s the Stem Cells Buzz this Week? - Regenerating the Diabetic Heart, Tissue Repair with Stem Cell-EVs, ESC-Derived Dopaminergic Neurons, and Trialing ADRCs for Breast Cancer-Related Lymphedema!
A roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond brought to you by the Stem Cells Portal!
Regenerating the Diabetic Heart: Reviewing the Challenges
Stem cell treatments to improve cardiac function are impaired in diabetic patients due to the progressive decline in the regenerative capacity of the stem cells themselves. Now, a new article from the labs of Rajesh Katare and Regis R Lamberts (University of Otago, Dunedin, New Zealand) aims to summarize the molecular alterations that reduce diabetic cardiac stem cell function to highlight possible strategies to improve this treatment option. See STEM CELLS for all the details!
The Promise of Tissue Repair with Stem Cell-EVs
The potent therapeutic activity of many stem cells is thought to derive from paracrine actions rather than the engraftment and differentiation at the injured sites. Extracellular vesicles (EVs) represent one such paracrine-acting factor, and the lab of Yang Wang (Shanghai Jiao Tong University, Shanghai, China) has recently published a report the therapeutic potential of stem cell-derived EVs in promoting tissue repair and regeneration. This new STEM CELLS Translational Medicine article mainly focuses on cutaneous wound healing, bone regeneration, hindlimb ischemia, and vascular injury repair.
Finding the Right Age for ESC-Derived Dopaminergic Neurons
Human embryonic stem cells-derived midbrain dopaminergic (mDA) neurons have potential as an exciting treatment option for Parkinson's disease (PD). The labs of Eng King Tan (National Neuroscience Institute), Steve Oh (A*STAR), and Li Zeng (National Neuroscience Institute, Singapore) sought to discover the optimal differentiation stage of mDA cells for PD therapy in their recent STEM CELLS Translational Medicine article. Interestingly, this study highlighted the usefulness of immature DA neurons (25 days) and DA neurons (35 days differentiation), but not DA progenitors (16 days). See the original study for all the fine print!
TrialingADRCs for Breast Cancer-Related Lymphedema
A new STEM CELLS Translational Medicine report provides us all the details on a new “First in Human Pilot Study” of adipose-derived stromal cells, rich in stem/progenitor cells, for the treatment of breast cancer-related lymphedema (BCRL). The lab of Jens Ahm Sørensen (Odense University, Denmark) demonstrates that autologous adipose-derived stromal cells alleviate symptoms and reduce dependence on other treatment options with no noteworthy adverse events. The authors hope that randomized clinical trials will confirm these positive results.
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!